Nurix Therapeutics Shares Slide as Widened Losses and New Equity Plan Spotlight Funding Challenge
Biotech firm Nurix Therapeutics reported a significant widening of its net loss for fiscal 2025 to $264.5 million, despite revenue growth. Concurrently, the company filed a shelf registration for a $98.8 million employee stock offering, raising fresh concerns over dilution and its path to profitability as its key drug candidates advance.